# Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis

> **NCT00475865** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 123 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Teriflunomide
- **DRUG:** Placebo (for teriflunomide)
- **DRUG:** Glatiramer Acetate (GA)

## Key facts

- **NCT ID:** NCT00475865
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2012-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00475865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00475865, "Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00475865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*